Clinical trials: Perturbation
Advanced Malignancies
Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.
- Trial name
- NCT00679133
- Testing
- MGCD265
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Mirati Therapeutics Inc.
Schizophrenia, Schizoaffective Disorder
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.
- Trial name
- NCT00141479
- Testing
- Bifeprunox
- Where
- United States
- Sponsor
- Solvay Pharmaceuticals
Fat Burn
Changes in Abdominal Tissues Induced by Magnetic Device - CT Evaluation
The study is a prospective multi-center open-label single-arm study. The subjects will be enrolled and assigned into a single study group.
- Trial name
- NCT03545646
- Testing
- Treatment with High Intensity Focused ElectroMagnetic system
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
HIV
An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
To test the hypothesis that AGT103-T cells therapy will allow HIV positive individual to reduce, modify or eliminate antiretroviral therapy.
- Trial name
- NCT05540964
- Testing
- Antiretroviral Therapy Interruption(ATI)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- American Gene Technologies International Inc.
Thighs Circumferential Reduction, Subcutaneous Fat Cell Disruption
Effect of the XP1100RF Therapy on Thighs Circumference Reduction
This study was designed to demonstrate safety and efficacy of the XP1100RF for non-invasive temporary reduction of thighs circumference by disruption of adipocyte cells.
- Trial name
- NCT02527369
- Testing
- XP1100RF
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression…
- Trial name
- NCT04819347
- Testing
- Albuvirtide, 3BNC117
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Frontier Biotechnologies Inc.
Pulmonary Embolism
RexMedical- Option* Vena Cava Filter IDE Study
This study is designed to evaluate the safety and efficacy of the RexMedical Option* Vena Cava Filter in the treatment of patients who are at increased risk for Pulmonary Embolism and require caval interruption.
- Trial name
- NCT00488865
- Testing
- Intravascular Filter Device
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Rex Medical
Type 2 Diabetes Mellitus
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes
The primary purpose of this study is to assess the anti-exenatide-antibody response to exenatide re-exposure as measured by anti-exenatide antibodies and incidence of treatment-emergent allergy and hypersensitivity reactions…
- Trial name
- NCT00516048
- Testing
- exenatide
- Where
- 13 sites in Australia, Canada and 3 more
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Glioblastoma Multiforme
ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2.0 used as a tool to disrupt the BBB in patients with Glioblastoma undergoing standard of care therapy.
- Trial name
- NCT03712293
- Testing
- BBB Disruption with Chemotherapy Arm
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- InSightec
Fat Burn
Fat Reduction Induced by Magnetic Device - Waist Circumference Evaluation
The study is a prospective multi-center open-label single-arm study. The subjects will be enrolled and assigned into a single study group.
- Trial name
- NCT03547934
- Testing
- High Intensity Focused ElectroMagnetic system.
- Where
- 2 sites in United States, Bulgaria
- Volunteers
- healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Parkinson Disease
Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease
This clinical trial focus on the delivery of Cerezyme® in Parkinson's Disease (PD) patients using MR-guided focused ultrasound (MRgFUS) induced opening of the blood-brain barrier (BBB).
- Trial name
- NCT04370665
- Testing
- Exablate BBBD with Cerezyme
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- InSightec
Brain Tumor
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric…
- Trial name
- NCT05615623
- Testing
- Exablate, Doxorubicin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- InSightec
Healthy Volunteers
Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model
The primary objective of the study is to investigate the effect of GSK2798745 on alveolar-septal barrier permeability following LPS challenge in healthy subjects.
- Trial name
- NCT03511105
- Testing
- GSK2798745, Lipoplysaccharide from Escherichia Coli, Saline
- Where
- Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Degenerative Sacroiliitis, Sacroiliac Joint Disruption
Sacroiliac Joint Fusion With iFuse Implant System (SIFI)
The purpose of this study is to evaluate the use of the iFuse Implant System to treat degenerative sacroiliitis (arthritis of the SI joint) and sacroiliac disruption (abnormal separation or tearing of the sacroiliac joint).
- Trial name
- SIFI (NCT01640353)
- Where
- 26 sites in United States
- Volunteers
- 194 people
- Sponsor
- SI-BONE, Inc.
Anhedonia, Major Depressive Disorder (MDD)
Efficacy of kTMP, a Novel Non-invasive Brain Stimulation Method, for the Treatment of Anhedonia
The goal of this proposal is to provide a first assessment of the efficacy of our innovative non-invasive brain stimulation system, kTMP, in the treatment of anhedonia in MDD.
- Trial name
- kTMP Anhedonia (NCT07032428)
- Testing
- A new non-invasive brain stimulation tool
- Volunteers
- 104 people
- Sponsor
- Magnetic Tides
Fat Burn
Changes in Abdominal Tissues Induced by Magnetic Device - MRI Evaluation
The study is a prospective multi-center open-label single-arm study. The subjects will be enrolled and assigned into a single study group.
- Trial name
- NCT03545633
- Testing
- Treatment with High Intensity Focused ElectroMagnetic system.
- Where
- 2 sites in United States, Bulgaria
- Volunteers
- healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Recurrent Glioblastoma
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing…
- Trial name
- NCT04417088
- Testing
- Carboplatin, Exablate BBBD
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- InSightec
Cardiovascular Diseases, Arrhythmias, Cardiac
Intracardiac Echocardiography Catheter Supply-Chain Reliability and Clinical Access Study
The ICE-ACCESS study is a prospective observational study designed to evaluate how procurement reliability, distribution restrictions, supply-chain interruptions, and device availability affect access to intracardiac…
- Conditions
- Cardiovascular Diseases, Arrhythmias, Cardiac, Atrial Fibrillation
- Trial name
- ICE-ACCESS (NCT07788040)
- Testing
- Intracardiac Echocardiography Catheter
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Truway Health, Inc.
Primary Myelofibrosis
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The aim of the study is to assess the efficacy and safety of restarting ruxolitinib after treatment interruption due to loss of response and/or adverse events.
- Trial name
- NCT02091752
- Testing
- Ruxolitinib
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Treatment Interruption of Natalizumab
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab.
- Trial name
- RESTORE (NCT01071083)
- Testing
- natalizumab, interferon beta 1-a, methylprednisolone
- Where
- 33 sites in United States, Germany and 1 more
- Volunteers
- 175 people
- Sponsor
- Biogen